Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2016 -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its fourth quarter and full year 2015 financial results on Thursday, March 10, 2016, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, March 10, 2016 at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company’s financial results and provide a general business update.
The live audio webcast may be accessed through the “Events & Presentations” page in the “Investors” section of the company’s website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 50136086.
The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
Company Contact: Heather Rowe Investor Relations 415-365-5737 [email protected]
